| Rheumatoid Arthritis

Celebrex vs Rituxan

Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.

Deep comparison between: Celebrex vs Rituxan with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsRituxan has a higher rate of injection site reactions vs Celebrex based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Rituxan but not Celebrex, including UnitedHealthcare

Category

Celebrex

Rituxan

At A Glance

RouteOral

FrequencyOnce or twice daily

ClassCOX-2 inhibitor

RouteIV infusion

ClassAnti-CD20 monoclonal antibody

Indications

Degenerative polyarthritis
Rheumatoid Arthritis
Juvenile rheumatoid arthritis
Ankylosing spondylitis
Primary dysmenorrhea

Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Rheumatoid Arthritis
Granulomatosis with polyangiitis
Microscopic Polyarteritis
Pemphigus Vulgaris
Acute lymphocytic leukemia

Dosing

Degenerative polyarthritis 200 mg once daily or 100 mg twice daily, oral.

Rheumatoid Arthritis 100 mg to 200 mg twice daily, oral.

Juvenile rheumatoid arthritis 50 mg twice daily for patients 10-25 kg; 100 mg twice daily for patients >25 kg, oral.

Ankylosing spondylitis 200 mg once daily or 100 mg twice daily, oral; if no effect after 6 weeks, may trial 400 mg daily.

Primary dysmenorrhea 400 mg initially, followed by 200 mg if needed on day 1; 200 mg twice daily on subsequent days, oral.

Lymphoma, Non-Hodgkin 375 mg/m2 IV; weekly for 4 or 8 doses for relapsed/refractory low-grade or follicular NHL; Day 1 of each chemotherapy cycle for up to 8 doses for previously untreated follicular or DLBCL; every 8 weeks for 12 doses as single-agent maintenance.

Acute lymphocytic leukemia 375 mg/m2 IV for 6 total infusions in combination with LMB chemotherapy (two doses during each of the two induction courses, one dose during each of the two consolidation courses) for pediatric patients aged 6 months and older.

Chronic Lymphocytic Leukemia 375 mg/m2 IV the day prior to initiation of cycle 1 FC chemotherapy, then 500 mg/m2 on Day 1 of cycles 2-6 every 28 days.

Rheumatoid Arthritis Two 1,000 mg IV infusions separated by 2 weeks per course in combination with methotrexate; subsequent courses every 24 weeks (no sooner than 16 weeks); premedicate with methylprednisolone 100 mg IV 30 minutes prior to each infusion.

Granulomatosis with polyangiitis, Microscopic Polyarteritis Induction: 375 mg/m2 IV once weekly for 4 weeks with glucocorticoids; follow-up: two 500 mg IV infusions separated by 2 weeks, then 500 mg IV every 6 months based on clinical evaluation.

Pemphigus Vulgaris Two 1,000 mg IV infusions separated by 2 weeks in combination with a tapering course of glucocorticoids; then 500 mg IV at Month 12 and every 6 months thereafter or based on clinical evaluation.

Contraindications

Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib or any components of the drug product
History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
Setting of CABG surgery
Demonstrated allergic-type reactions to sulfonamides

—

Drug Interactions

1343View drug interactions

537View drug interactions

Adverse Reactions

Most common (>=2%) Headache, dyspepsia, upper respiratory infection, diarrhea, sinusitis, abdominal pain, nausea, back pain, peripheral edema, rhinitis, pharyngitis, rash, flatulence, dizziness, insomnia.

Serious Cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, hematologic toxicity.

Postmarketing Vasculitis, deep venous thrombosis, angioedema, liver necrosis, hepatic failure, agranulocytosis, aplastic anemia, pancytopenia, aseptic meningitis, fatal intracranial hemorrhage, interstitial nephritis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, DRESS, AGEP, fixed drug eruption.

Most common (>=25%) Infusion-related reactions, fever, lymphopenia, chills, infection, asthenia (in NHL); infusion-related reactions, neutropenia (in CLL)

Serious Fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B reactivation with fulminant hepatitis, progressive multifocal leukoencephalopathy, tumor lysis syndrome, sepsis, cardiovascular events, renal toxicity, bowel obstruction and perforation

Postmarketing Prolonged pancytopenia, fatal cardiac failure, progressive multifocal leukoencephalopathy, severe mucocutaneous reactions, pyoderma gangrenosum, bowel obstruction and perforation, fatal bronchiolitis obliterans, fatal interstitial lung disease, posterior reversible encephalopathy syndrome

Pharmacology

Celecoxib is a selective COX-2 inhibitor that reduces prostaglandin synthesis in peripheral tissues and the CNS, producing analgesic, anti-inflammatory, and antipyretic effects; at therapeutic doses it does not inhibit platelet aggregation or prolong bleeding time.

Rituximab is a chimeric murine/human IgG1 kappa monoclonal antibody that binds the CD20 antigen on pre-B and mature B-lymphocytes, mediating B-cell lysis via complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC).

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Celebrex